27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Oragenics Inc (NYSE: OGEN) stock is soaring higher after announcing a deal related to its Terra CoV-2 vaccine candidate against COVID-19.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
- Oragenics has reached an agreement with Biodextris that will allow it to use Biodextris' BDX100, BDX300, and BDX301 proteosome-based adjuvants in the Terra CoV-2 vaccine.
- Adjuvants are added to vaccines to enhance their immunogenicity. BDX100, BDX300, and BDX301 are proteosome-based adjuvants comprised of proteins and lipopolysaccharides with the benefits of intranasal vaccine administration.
- Oragenics plans to start with animal testing of the vaccine in combination with the adjuvants.
- The deal between Oragenics and Biodextris also allows for a potential expansion in the future. That includes use in a commercial vaccine if Terra CoV-2 gets approval from the FDA.
- Price Action: OGEN shares increased 38.5% at $1.17 in market trading hours on the last check Tuesday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.